Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ranbaxy Recalls Statin Drug Batches
by Jean-François Tremblay
December 10, 2012
| A version of this story appeared in
Volume 90, Issue 50
Ranbaxy Laboratories’ U.S. subsidiary has recalled 41 lots of atorvastatin, the company’s generic version of the Pfizer drug Lipitor, because they may contain sand-sized glass particles. So far no one has reported an adverse reaction, the company says. The recall is another blow to Ranbaxy’s image. The firm reached an agreement with FDA less than a year ago about how to address manufacturing problems discovered in 2008 at Ranbaxy plants in northern India.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter